Does Rallies show Form 4 insider transactions for SRRK?

Yes. Rallies tracks SRRK insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SRRK research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SRRK. It does not provide personalized investment advice.

SRRK (Scholar Rock Holding Corporation Common Stock) Stock Analysis - Insider Trades

Scholar Rock Holding Corporation Common Stock (SRRK) is a publicly traded Healthcare sector company. As of May 20, 2026, SRRK trades at $48.35 with a market cap of $5.68B and a P/E ratio of -14.80. SRRK moved +1.68% today. Year to date, SRRK is +13.14%; over the trailing twelve months it is +53.39%. Its 52-week range spans $6.76 to $51.63. Analyst consensus is strong buy with an average price target of $60.17. Rallies surfaces SRRK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SRRK stock inside the company?

Recent SRRK insider activity includes Woods Keith sold 10.22K, Vaishnaw Akshay sold 12.25K, Sinha Vikas sold 10.41K, Hallal David sold 30.61K, and Qatanani Mo sold 7.43K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SRRK Key Metrics

Key financial metrics for SRRK
Metric	Value
Price	$48.35
Market Cap	$5.68B
P/E Ratio	-14.80
EPS	$-3.29
Dividend Yield	0.00%
52-Week High	$51.63
52-Week Low	$6.76
Volume	765.77K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-377.94M
Gross Margin	0.00%

Recent SRRK Insider Trades

Woods Keith sold 10.22K (~$506.65K) on Apr 16, 2026.
Vaishnaw Akshay sold 12.25K (~$607.09K) on Apr 16, 2026.
Sinha Vikas sold 10.41K (~$516.07K) on Apr 16, 2026.
Hallal David sold 30.61K (~$1.52M) on Apr 16, 2026.
Qatanani Mo sold 7.43K (~$348.64K) on Feb 23, 2026.

Latest SRRK News

Scholar Rock slides as Q1 results highlight apitegromab BLA acceptance and site reinspection — May 7, 2026
Scholar Rock rises as apitegromab FDA resubmission refocuses bulls on September 2026 decision — Apr 28, 2026
Scholar Rock slides as post-SRC compliance costs and dilution fears weigh on shares — Apr 22, 2026
Scholar Rock drops as investors price dilution risk after recent FDA BLA resubmission rally — Apr 20, 2026
Scholar Rock slides as apitegromab approval timing uncertainty returns to focus — Mar 28, 2026

SRRK Analyst Consensus

15 analysts cover SRRK: 0 strong buy, 15 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $60.17.

Common questions about SRRK

Who is trading SRRK stock inside the company?: Recent SRRK insider activity includes Woods Keith sold 10.22K, Vaishnaw Akshay sold 12.25K, Sinha Vikas sold 10.41K, Hallal David sold 30.61K, and Qatanani Mo sold 7.43K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SRRK?: Yes. Rallies tracks SRRK insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SRRK research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SRRK. It does not provide personalized investment advice.